Akebia Therapeutics, Inc. announces key corporate updates related to Vafseo® (vadadustat) commercial business and upcoming milestones in the rare kidney disease pipeline.
The company is positioned to increase the depth of Vafseo prescribing and has dosed the first patient in a Phase 2 clinical trial for focal segmental glomerulosclerosis.
Akebia's AKB-097 Phase 2 rare kidney disease basket trial is set to begin in the second half of 2026 with initial data expected in 2027.
Vafseo Achievements in 2025
Secured broad prescribing access for Vafseo, completed enrollment in the VOICE trial, presented positive analysis at ASN Kidney Week, and enrolled patients in the VOCAL trial.
Vafseo Q4 2025 Performance Expectations
Increased prescribers, growth in new patients from different dialysis organizations, and revenue expectations for Q4.
Rare Kidney Disease Pipeline Activities
Praliciguat Phase 2 trial for FSGS underway, plans to explore use in other rare kidney diseases, and upcoming AKB-097 Phase 2 trial details.
- Akebia is set for growth in 2026 with plans to drive Vafseo adoption, present trial results, and progress its rare kidney disease pipeline.
- The company's revenue-generating products and scientific leadership in nephrology position it to create shareholder value in the coming year.
Akebia Therapeutics looks ahead to a promising year with strong financial standing, anticipated demand for Vafseo, and the advancement of its rare kidney disease pipelines.